 |
|
Mechanisms of High-Dose Intravenous Immunoglobulins in Demyelinating Diseases
Martin Stangel, MD;
Klaus V. Toyka, MD;
Ralf Gold, MD
Arch Neurol. 1999;56:661-663.
Administration of high-dose intravenous immunoglobulins has become one of the most successful new treatment regimens for demyelinating diseases. In a decade of molecular medicine, it came as a surprise that a natural blood product would prove effective in several disorders, including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and, probably, multiple sclerosis. Many experimental studies, both in vivo and in vitro, have shown that intravenous immunoglobulins can interfere with the immune system at several levels. In addition, intravenous immunoglobulins may promote remyelination in demyelinating disease associated with viral infections. At present, no single mode of action has been identified as the crucial mechanism, which leads us to suggest that multiple effects may act in concert.
From the MRC Centre for Brain Repair, Cambridge University, Cambridge, England (Dr Stangel); and the Department of Neurology and the Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Julius Maximilians Universität, Würzburg, Germany (Drs Toyka and Gold).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(6):762-764.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions
Stuve et al.
Arch Neurol 2007;64:169-176.
ABSTRACT
| FULL TEXT
Systemic lupus erythematous with recurrent Guillain -Barre-like syndrome treated with intravenous immunoglobulins
Lewis and Gibson
Lupus 2003;12:857-859.
ABSTRACT
Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor
Petereit et al.
Mult Scler 2003;9:16-20.
ABSTRACT
Peripheral neuropathies and anti-glycolipid antibodies
Willison and Yuki
Brain 2002;125:2591-2625.
ABSTRACT
| FULL TEXT
Despair of repair
Stangel and Hartung
J. Neurol. Neurosurg. Psychiatry 2002;72:1-4.
FULL TEXT
IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial
Noseworthy et al.
Neurology 2000;55:1135-1143.
ABSTRACT
| FULL TEXT
Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis
Warrington et al.
Proc. Natl. Acad. Sci. USA 2000;97:6820-6825.
ABSTRACT
| FULL TEXT
|
